Document is current
Any future updates will be listed below
-
Authors
Howell, Katherine B. https://orcid.org/0000-0002-5469-8411
White, Susan M.
McTague, Amy https://orcid.org/0000-0002-0334-2909
D’Gama, Alissa M.
Costain, Gregory https://orcid.org/0000-0003-0099-9945
Poduri, Annapurna https://orcid.org/0000-0002-7350-5136
Scheffer, Ingrid E. https://orcid.org/0000-0002-2311-2174
Chau, Vann
Smith, Lindsay D.
Stephenson, Sarah E. M.
Wojcik, Monica https://orcid.org/0000-0002-8162-5031
Davidson, Andrew
Sebire, Neil
Sliz, Piotr https://orcid.org/0000-0002-6522-0835
Beggs, Alan H. https://orcid.org/0000-0001-8818-0568
Chitty, Lyn S.
Cohn, Ronald D.
Marshall, Christian R. https://orcid.org/0000-0002-4003-7671
Andrews, Nancy C. https://orcid.org/0000-0003-0243-4462
North, Kathryn N.
Cross, J. Helen
Christodoulou, John https://orcid.org/0000-0002-8431-0641
Scherer, Stephen W. https://orcid.org/0000-0002-8326-1999
- License Information
-
More Information
Article History
Received: 5 September 2024
Accepted: 29 January 2025
First Online: 27 February 2025
Competing interests
: K.B.H. has received research funding from UCB Australia, Praxis Precision Medicines and RogCon Biosciences, Inc., has served on an advisory board for UCB Australia, and is a member of the Scientific and Medical Board for SCN2A Asia-Pacific. N.C.A. is on the Boards of Directors of Novartis, Charles River Laboratories and Maze Therapeutics, and the Scientific Advisory Board of Dyne Therapeutics. A.H.B. has received consulting fees from Astellas Gene Therapies, GLG Inc., Guidepoint Global, and F. Hoffman-La Roche, is on the Scientific Advisory Board of Kate Therapeutics, and holds equity in Kate Therapeutics and Kinea Bio. J.H.C. has acted as an investigator for studies with GW Pharma/Jazz Pharmaceuticals, Zogenix/UCB Pharma, Vitaflo, Stoke Therapeutics, and Ultragenyx. She has been a speaker and on advisory boards for Jazz Pharmaceuticals, UCB, Biocodex, and Nutricia; all remuneration has been paid to her department. J.C. is a member of the Drug Monitoring and Safety Board for Anavex Life Sciences Corp, the Endpoint Adjudication Committee for Taysha Gene Therapies, the Scientific and Medical Advisory Committees of the Childhood Dementia Initiative and the Rett Syndrome Association of Australia, and is the director of the Mito Foundation of Australia. S.W.S. served on the scientific advisory committee of Population Bio, Deep Genomics and intellectual property from his research held at the Hospital for Sick Children and licensed to Athena Diagnostics and Population Bio. S.W.S., R.D.C., and C.R.M. are Editors or Editorial Board Members of npj Genomic Medicine; they were not part of the peer review or decision-making processes for this manuscript. S.M.W., A.McT., A.M.D., G.C., A.P., I.E.S., V.C., L.D.S., S.E.M.S., M.W., A.D., N.S., P.S., L.S.C., and K.N.N. report no competing interests.
